MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

被引：0

作者：

Ou, S. H. ^{[1
]}

Garcia, V. Moreno ^{[2
]}

Bazo, I. Gil ^{[3
]}

Prenen, H. ^{[4
]}

Moreno, I. ^{[5
]}

Johnson, M. ^{[6
]}

Alvarez, E. Castanon ^{[7
]}

Nagasaka, M. ^{[1
]}

Adeyemi, S. ^{[8
]}

Barasa, B. ^{[9
]}

Bol, K. ^{[10
]}

Doze, P. ^{[10
]}

Engbers, A. ^{[10
]}

Joe, A. K. ^{[10
]}

Stalbovskaya, V. ^{[8
]}

Laus, G. ^{[10
]}

Call, J. ^{[11
]}

机构：

[1] Univ Calif Irvine, Dept Med Div Hematol Oncol, Sch Med, Irvine, CA USA

[2] Start Madrid FJD, Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[3] Univ Navarra Clin, Dept Med Oncol, Pamplona, Spain

[4] Univ Antwerp Hosp, Oncol, Antwerp, Belgium

[5] HM Sanchinarro Univ Hosp, Start Madrid, CIOCC, Madrid, Spain

[6] Sarah Cannon Res Inst LLC, Lung Canc Res, Nashville, TN USA

[7] Univ Navarra Clin, Dept Med Oncol, Madrid, Spain

[8] Merus, Biometr, Utrecht, Netherlands

[9] Merus, Translat Res, Utrecht, Netherlands

[10] Merus, Clin, Utrecht, Netherlands

[11] START Mt Reg, Med Oncol, Salt Lake City, UT USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

341

引用

页码：S122 / S122

页数：1